Pediatric Rare Disease Insurance Denied: Gene Therapy, Orphan Drugs, and Appeal Guide

Rare diseases disproportionately affect children. Of the 7,000+ identified rare diseases, approximately 70% begin in childhood. About 50% of people affected by rare diseases are children, and rare diseases are responsible for 35% of deaths in the first year of life. For children with rare diseases, access to the right treatment — often a recently approved or investigational therapy — can be the difference between life and death, or between independence and lifelong disability.

Insurance denials for rare disease treatments present unique challenges, but the legal and regulatory framework provides meaningful tools for families willing to appeal.

FDA Orphan Drug Designation

The Orphan Drug Act of 1983 created a special designation for drugs developed to treat rare diseases affecting fewer than 200,000 Americans. FDA orphan drug designation provides drug developers with incentives (tax credits, user fee waivers, 7-year market exclusivity) to create treatments for conditions that would otherwise be too unprofitable to develop.

When a drug carries FDA orphan drug designation and is prescribed for the condition for which designation was granted, this is significant evidence that the FDA has recognized the drug as targeting a serious rare condition. Insurers who deny coverage by calling an orphan drug "experimental" are ignoring the FDA's own classification.

In your appeal, include a printout of the FDA's orphan drug designation record for the drug, which is publicly searchable in the FDA Orphan Drug Product Designation Database. Note the specific indication and the granted designation date.

Zolgensma and Gene Therapy for Spinal Muscular Atrophy

Zolgensma (onasemnogene abeparvovec) is a gene therapy for spinal muscular atrophy (SMA) Type 1, the leading genetic cause of infant death. A single dose replaces the missing SMN1 gene and can transform the disease course for infants treated before symptom onset. It was approved by the FDA in May 2019.

Zolgensma's list price (~$2.1 million at approval) made it among the most expensive drugs ever approved at that time. Insurance denials take several forms:

• Age or weight limit denials. FDA approval is for patients under 2 years. Insurance criteria may impose additional age or weight restrictions.
• Prior treatment requirements. Some insurers require a trial of Spinraza (nusinersen, another SMA treatment) before approving Zolgensma. This requirement may be clinically inappropriate for infants identified through newborn screening, where early gene therapy provides the best outcomes.
• Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization with narrow criteria. Some plans apply criteria that are more restrictive than the FDA label.

To appeal a Zolgensma denial:

1. Include the FDA-approved label for Zolgensma and document that your child meets the FDA-approved indication
2. Obtain a letter from the SMA specialist documenting urgency — early treatment provides significantly better outcomes
3. Challenge step therapy requirements that require Spinraza first as clinically inappropriate per SMA Foundation and AAN guidelines
4. For Medicaid/CHIP: invoke EPSDT

Expanded Access and Compassionate Use Programs

When a drug has not yet been FDA-approved but shows promise in clinical trials, families may be able to access it through expanded access (also known as compassionate use) programs. The FDA allows manufacturers to provide investigational drugs to patients with serious or life-threatening conditions outside of clinical trials.

Insurance coverage for drugs provided through expanded access is inconsistent. Most insurers consider expanded access drugs "investigational" and exclude them from coverage. However, the routine costs of care associated with an approved expanded access program may be covered under the ACA's clinical trial protection provisions.

NORD (National Organization for Rare Disorders) maintains a resource database including information about expanded access programs for rare diseases. The FDA's expanded access database is publicly searchable at clinicaltrials.gov.

NORD Patient Assistance Database

NORD (National Organization for Rare Disorders) operates several programs to assist families with rare disease treatment access:

• NORD Rare Disease Database: comprehensive information about specific rare diseases and available treatments
• NORD Patient Assistance Programs: co-pay assistance and free medication programs for patients who cannot afford their treatments
• NORD Rare Disease Centers of Excellence: a network of specialized rare disease clinics

When appealing a rare disease drug denial, contact NORD to identify whether patient assistance programs are available. While these programs provide short-term access, they do not substitute for proper insurance coverage and should not discourage appeal.

Building a Rare Disease Appeal

An effective rare disease insurance appeal should include:

1. FDA approval documentation, orphan drug designation records, or breakthrough therapy designation, as applicable
2. A letter from the treating specialist at a rare disease center of excellence or academic medical center
3. Documentation of the natural history of the disease without treatment and the expected benefit of the denied treatment
4. Peer-reviewed literature supporting the treatment's safety and efficacy for the specific condition
5. For Medicaid/CHIP: EPSDT citation (42 U.S.C. § 1396d(r))
6. A request for an expedited review given the progressive or life-threatening nature of many rare diseases

External independent medical review is particularly valuable for rare disease denials. Request an External Independent Review: Complete Guide" class="auto-link">external review by an independent organization organization with expertise in the specific disease, not a generalist reviewer.

Fight Back With ClaimBack

Insurance denials for rare pediatric diseases compound a family's worst nightmare. ClaimBack helps families craft comprehensive, evidence-backed appeals for rare disease treatments that give children the best possible chance of getting life-changing care.

Start your rare disease appeal at ClaimBack

Related Reading

• What Is Medical Necessity?
• How to Write an Insurance Appeal Letter
• Internal vs. External Insurance Appeal: Which Should You File?